In the TCGA cohort, individuals with higher CD28 and individuals with higher FLT3LG expression had higher survival than those with lower CD28 expression and those with lower FLT3LG expression (Fig. 4), showing that less immunosuppressed individuals were better able to combat cancer [28]. The gene discussed is CD28; the disease is cancer.